Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors

Trial Profile

Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2016

At a glance

  • Drugs Everolimus (Primary) ; Prednisone
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms PREV
  • Most Recent Events

    • 30 Dec 2015 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 02 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top